Last updated on July 2018

A Study to Evaluate ABY-035 in Subjects With Moderate-to-severe Plaque Psoriasis


Brief description of study

This randomized, double-blinded dose-finding study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis.

The study consists of a four week screening period, three treatment periods of a total of 48 weeks, and a four-week follow-up period.

The subjects are randomized to one out of four dose levels, or placebo (1:1:1:1:1). After the first 12 weeks of treatment, the subjects randomized to placebo will receive active treatment. The dose levels and dosing intervals are adjusted depending on the absolute PASI score, to obtain an individualized treatment regimen.

Detailed Study Description

The study evaluates four dose levels of ABY-035, in comparison to placebo, in subjects with moderate to severe plaque psoriasis.

The study consists of a four week screening period, three treatment periods and a four-week follow-up period.

The treatment periods are:

  1. Randomized treatment; four dose levels and placebo. Biweekly (Q2W) administration during during 12 weeks.
  2. Administration Q2W during during 12 weeks, starting with a possible dose adjustment depending on the achieved absolute PASI score. Subjects on placebo are switched to active drug every 4 weeks (Q4W).
  3. Administration Q4W, starting with a possible dose adjustment , depending on the achieved absolute PASI score. The dosing interval is varied between Q4W and Q8W, depending on the PASI score.

Clinical Study Identifier: NCT03591887

Contact Investigators or Research Sites near you

Start Over

Peter Radny, Dr.

Derma-Study-Center FN GmbH
Friedrichshafen, Germany
1.9miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.